Association between PRS and GEC CLL/MBL/controls risk compared with Mayo Clinic controls
| . | Mayo controls (N = 1267) . | GEC controls (N = 144) . | GEC MBL (N = 95) . | GEC CLL (N = 201) . | GEC CLL (N = 201) vs Mayo controls . | GEC MBL (N = 95) vs Mayo controls . | GEC Controls (N = 144) vs Mayo controls . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRS (range)* . | N . | % . | N . | % . | N . | % . | N . | % . | OR† . | CI . | P . | OR† . | CI . | P . | OR† . | CI . | P . |
| Q1 (4.32-6.80) | 228 | 18.0 | 18 | 12.5 | 2 | 2.1 | 3 | 1.5 | 0.14 | 0.04-0.46 | .001 | 0.19 | 0.04-0.85 | .03 | 0.86 | 0.45-1.67 | .66 |
| Q2 (6.80-7.32) | 261 | 20.6 | 16 | 11.1 | 6 | 6.3 | 19 | 9.5 | 0.76 | 0.40-1.43 | .39 | 0.49 | 0.18-1.35 | .17 | 0.67 | 0.34-1.32 | .25 |
| Q3 (7.32-7.77) | 230 | 18.2 | 21 | 14.6 | 11 | 11.6 | 23 | 11.4 | Ref | — | — | Ref | — | — | Ref | — | — |
| Q4 (7.77-8.28) | 265 | 20.9 | 28 | 19.4 | 19 | 20.0 | 32 | 15.9 | 1.21 | 0.68-2.13 | .52 | 1.50 | 0.70-3.23 | .3 | 1.16 | 0.64-2.09 | .63 |
| Q5 (8.28-11.31) | 283 | 22.3 | 61 | 42.4 | 57 | 60.0 | 124 | 61.7 | 4.47 | 2.76-7.24 | 1.20 × 10−9 | 4.34 | 2.21-8.50 | 1.90 × 10−5 | 2.38 | 1.41-4.03 | .001 |
| Continuous | 3.02 | 2.49-3.65 | 7.79 × 10−30 | 2.81 | 2.18-3.61 | 9.75 × 10−16 | 1.66 | 1.37-2.02 | 3.00 × 10−7 | ||||||||
| PRS (median) | 7.59 | 8.09 | 8.40 | 8.51 | |||||||||||||
| c-statistics | 0.779 | 0.74-0.81 | 0.774 | 0.73-0.82 | 0.635 | 0.58-0.69 | |||||||||||
| . | Mayo controls (N = 1267) . | GEC controls (N = 144) . | GEC MBL (N = 95) . | GEC CLL (N = 201) . | GEC CLL (N = 201) vs Mayo controls . | GEC MBL (N = 95) vs Mayo controls . | GEC Controls (N = 144) vs Mayo controls . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRS (range)* . | N . | % . | N . | % . | N . | % . | N . | % . | OR† . | CI . | P . | OR† . | CI . | P . | OR† . | CI . | P . |
| Q1 (4.32-6.80) | 228 | 18.0 | 18 | 12.5 | 2 | 2.1 | 3 | 1.5 | 0.14 | 0.04-0.46 | .001 | 0.19 | 0.04-0.85 | .03 | 0.86 | 0.45-1.67 | .66 |
| Q2 (6.80-7.32) | 261 | 20.6 | 16 | 11.1 | 6 | 6.3 | 19 | 9.5 | 0.76 | 0.40-1.43 | .39 | 0.49 | 0.18-1.35 | .17 | 0.67 | 0.34-1.32 | .25 |
| Q3 (7.32-7.77) | 230 | 18.2 | 21 | 14.6 | 11 | 11.6 | 23 | 11.4 | Ref | — | — | Ref | — | — | Ref | — | — |
| Q4 (7.77-8.28) | 265 | 20.9 | 28 | 19.4 | 19 | 20.0 | 32 | 15.9 | 1.21 | 0.68-2.13 | .52 | 1.50 | 0.70-3.23 | .3 | 1.16 | 0.64-2.09 | .63 |
| Q5 (8.28-11.31) | 283 | 22.3 | 61 | 42.4 | 57 | 60.0 | 124 | 61.7 | 4.47 | 2.76-7.24 | 1.20 × 10−9 | 4.34 | 2.21-8.50 | 1.90 × 10−5 | 2.38 | 1.41-4.03 | .001 |
| Continuous | 3.02 | 2.49-3.65 | 7.79 × 10−30 | 2.81 | 2.18-3.61 | 9.75 × 10−16 | 1.66 | 1.37-2.02 | 3.00 × 10−7 | ||||||||
| PRS (median) | 7.59 | 8.09 | 8.40 | 8.51 | |||||||||||||
| c-statistics | 0.779 | 0.74-0.81 | 0.774 | 0.73-0.82 | 0.635 | 0.58-0.69 | |||||||||||